Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

July 6, 2018: By Jon Swedien

Opthea has enrolled 176 patients, about half its planned total, in a Phase IIb trial of its wet age-related macular degeneration (AMD) candidate, the company announced July 2.

The Melbourne, Australia, firm said it remains on track to report data from the study in early 2020.

The candidate is OPT-302, a VEGF-C/D inhibitor. The study is designed to determine if OPT-302 improves visual acuity and anatomical parameters, such as retinal fluid and thickness, in patients receiving standard of care anti-VEGF-A therapy for wet AMD.

The study will randomize patients in a 1:1:1 ratio. One group will receive OPT-302 administered at 0.5 mg in combination with Lucentis (ranibizumab, 0.5 mg). Another group will receive 2 mg of OPT-302 in combination with Lucentis. A third group will receive only Lucentis and a sham injection.

Treatments will be administered on a monthly basis for six months via intravitreal injection.

Opthea also has a Phase Ib/IIa trial for OPT-302 as a treatment candidate for diabetic macular edema.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales